Bis(6-((4-(4-fluorophenyl)piperidin-3-yl)methoxy)benzo[d][1,3]dioxol-5-yl)methane

Catalog No. :
ACQEWP764
CAS No. :
606968-05-2
Molecular Formula :
C39H40F2N2O6
Molecular Weight :
670.75

IUPAC Name:bis(6-((4-(4-fluorophenyl)piperidin-3-yl)methoxy)benzo[d][1,3]dioxol-5-yl)methane

Bis(6-((4-(4-fluorophenyl)piperidin-3-yl)methoxy)benzo[d][1,3]dioxol-5-yl)methane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBis(6-((4-(4-fluorophenyl)piperidin-3-yl)methoxy)benzo[d][1,3]dioxol-5-yl)methane
IUPAC Namebis(6-((4-(4-fluorophenyl)piperidin-3-yl)methoxy)benzo[d][1,3]dioxol-5-yl)methane
Molecular FormulaC39H40F2N2O6
Molecular Weight670.75
SMILESFC1=CC=C(C2C(COC3=C(CC4=C(OCC5CNCCC5C6=CC=C(F)C=C6)C=C(OCO7)C7=C4)C=C8OCOC8=C3)CNCC2)C=C1
InChI KeyVKTXNNYQYBNOJB-UHFFFAOYSA-N
SynonymMethylene-Bis Paroxetine Dihydrochloride;3,3'-[Methylenebis(1,3-benzodioxole-6,5-diyloxyMethylene)]bis [4-(4-fluorophenyl)piperidine DiHydrochloride;Bis(3,4-Methylenedioxy-6-[(3S,4R)-4-(4-fluorophenyl)piperidine-3-ylMethoxy]Methane DiHydrochloride;Paroxetine EP IMpurity F;Bis {3,4-methylenedioxy-6-[(3S,4R)-4-(4-fluorophenyl) piperidine-3 -ylmethoxy]phenyl} methane;Paroxetine HCl Hemihydrate EP Impurity F;Paroxetine Impurity 7(Paroxetine HCl Hemihydrate EP Impurity F);Paroxetine Dimer
CAS No.606968-05-2

Synthetic Route by SureRoute

1. ACQEWP764 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQEWP764 route product structure diagram
    ACQEWP764606968-05-2
Inquiry

2. ACQEWP764 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQEWP764 route product structure diagram
    ACQEWP764606968-05-2
Inquiry

Comments (0)